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ABSTRACT 
Aim: To evaluate possible effects of smoking on clinical, biochemical, and microbiological 
outcomes of non-surgical periodontal treatment in patients with periodontitis stage III or IV. 
Material and Method: Conventional quadrant-wise non-surgical periodontal treatment was 
performed and whole-mouth periodontal measurements were recorded at baseline, 1-, 3-, 6-
months after completion of treatment. Saliva, gingival crevicular fluid, subgingival plaque, and 
blood samples were obtained at the same time points. Inflammatory cytokine levels, presence, 
and quantities of 11 different bacterial species were determined. Smoking status was validated 
by cotinine assay.  
Results: Fourteen smoker and 13 non-smoker patients completed the study protocol and 
revealed similar clinical findings except for the higher plaque scores in the non-smokers at 6-
months (p<0.01). Significant differences were found between the study groups in biofluid 
cytokine levels at 1-, 3-months (p<0.01). Gram-negative bacteria were more abundant in the 
smokers at baseline and so were Gram-positive bacteria in the non-smokers (p<0.01). Gram-
negative bacteria repopulated in the smokers faster than in the non-smokers (p<0.01). 
Conclusion: The present findings suggest that smoker patients with periodontitis stage III and 
IV respond well to the non-surgical periodontal treatment during the 6-month follow-up. 
However, smokers exhibit faster repopulation of Gram-negative bacteria. 
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INTRODUCTION 
Smoking is the major preventable risk factor in the initiation and progression of periodontal 
diseases. Smokers have more severe periodontal disease; more pocketing, more bone loss, more 
attachment loss, more gingival recession, and more susceptibility for tooth loss.1 Furthermore, 
smoking adversely affects the outcomes of non-surgical periodontal treatment.2 Less reduction 
in probing depth and clinical attachment gain have been found in smoker periodontitis patients 
compared to their non-smoker counterparts following non-surgical periodontal treatment.3 
Smoker patients with aggressive periodontitis (AgP) have been reported not to respond well to 
mechanical non-surgical periodontal treatment.4 Accordingly, smoking has been associated 
with an increased risk for recurrence of periodontitis in AgP patients.5 
AgP is characterized by attachment loss that is usually incompatible with the amount of 
plaque and dental calculus.6 Few studies have investigated the success of non-surgical 
periodontal therapy in AgP patients and it is often not possible to predict the prognosis of 
various treatment options.7 Rosalem et al.8 compared the response to non-surgical periodontal 
therapy in GAgP and generalized chronic periodontitis patients using clinical, immunologic and 
microbiological data and suggested that the treatment response was similar in both groups. 
The interleukin-17 (IL-17) family is composed of six members (IL-17A-IL-17F). IL-17A, 
IL-17F homodimers and IL-17A/F heterodimer have been demonstrated to drive expression of 
antimicrobial peptides, cytokines, chemokines, and matrix metalloproteinases from fibroblasts, 
endothelial and epithelial cells and therefore, have pro-inflammatory properties.9 In contrast, 
IL-17E has been shown not only to be a driver of a T helper-2 immune response but also a 
suppresser of the destructive pro-inflammatory responses.10 Indeed, IL-17E has been shown to 
inhibit IL-17A and P. gingivalis induced nuclear factor-kappa B (NFB) activity.10 Therefore, 
IL-17E is likely to have opposing biological effects to IL-17A, IL-17F and IL-17A/F. During 
the inflammatory response, pro-inflammatory cytokines such as IL-1β, IL-6, IL-11, IL-17A, 
IL-17F and tumour necrosis factor-alpha (TNF-α) can induce alveolar bone resorption by 
increasing the expression of receptor activator of NFB ligand (RANKL) and reducing 
osteoprotegerin (OPG) production from osteoblasts and stromal cells.10 In a recent study, it was 
stated that systemic cytokine signaling via IL-17 is impaired in smokers and this impairment is 
associated with bacterial colonization by opportunistic pathogens locally in the airways.11 Many 
studies suggested that IL-17 has a significant role in the pathogenesis of periodontal diseases.12-
14 
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Smoking affects host cytokine levels in biofluids15 and pathopionts are more abundant in 
the subgingival microflora of smokers.16 However, the exact mechanisms of the detrimental 
effects of smoking on periodontal tissues remain unclear.17 It was hypothesised that non-smoker 
patients with GAgP will respond better in terms of the clinical, biochemical and microbiological 
parameters to the conventional mechanical non-surgical periodontal treatment compared to the 
smoker counterparts. Therefore, the aim of this study was to evaluate possible effects of 
smoking on the outcomes of non-surgical periodontal treatment.  
MATERIALS and METHODS 
Study population 
A total of 48 Caucasian patients were screened and 34 patients with the clinical and the 
radiological diagnosis of GAgP were recruited for this study between June 2014 and August 
2015. The diagnosis of GAgP was assigned in accordance with the clinical criteria stated in the 
consensus report of the World Workshop in Periodontitis.18 According to the consensus report 
published by Papapanou et al.19 the patients included in the present study comply with the 
definition of periodontitis Stage III or IV with regard to the extent and severity and Grade C 
due to the early onset of the disease. These patients had at least one site with probing depth 
(PD) and clinical attachment level (CAL) ≥5 mm in their incisors and/or first molars and at 
least six other teeth with similar PD and CAL measurements, and familial aggregation (all 
individuals were asked if they had any family member with current or history of severe 
periodontal disease). Smokers were those who reported smoking more than 10 cigarettes/day 
for more than 5 years, while non-smokers were those who reported that they had never smoked. 
Smoking status was validated with salivary cotinine analysis.  
The study was approved by the Ethics Committee of Ege University, İzmir, Turkey 
(Protocol number; 14-9/28) and registered to the US National Institutes of Health Clinical Trials 
Registry site with the ID number of NCT03512938. Full accordance with ethical principles 
including the World Medical Association’s Declaration of Helsinki as revised in 2000 was 
provided. The study protocol was explained and written informed consent was received from 
each individual before clinical periodontal examinations and sampling. Medical and dental 
histories were obtained. Exclusion criteria included presence of less than 15 teeth, known 
medical disorders such as diabetes mellitus, rheumatoid arthritis, immunological disorders and 
history of antibiotic, anti-inflammatory or periodontal treatment in the preceding 6 months.  
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Sample Size Calculation 
A two-sided two-sample t-test with a significance level of 5% was used for the sample size 
calculation. Based on this analysis, a sample size of 12 subjects for each group was estimated 
to be necessary to achieve 80% power to detect a difference of 1 mm (SD 0.85) between the 
two groups in the mean PD reduction. A total of 34 were to be selected to compensate for a 
possible drop-out during the course of the study. 
Non-surgical periodontal therapy 
Patients were motivated and instructed to brush twice a day with the modified Bass technique 
and use interdental toothbrushes and dental floss once a day regularly. Each patient underwent 
quadrant-wise scaling and root planing (SRP) over a 4-week period. Root planing (RP) was 
performed under local anaesthesia (2% lidocaine, epinephrine 1:100.000) and a standard curette 
set‡ newly sharpened with a stone§ was used for each patient. A single researcher (BK) 
performed SRP in all patients. The procedures were continued until a hard, smooth root surface 
was sensed with an explorer tip.  
Clinical measurements 
Clinical periodontal measurements were performed by a calibrated periodontist (BK) at 
baseline and also 1-, 3-, and 6-months after completion of SRP. Saliva, serum, gingival 
crevicular fluid (GCF), and subgingival plaque samples were collected at the same time points. 
Calibration of the investigator was performed with measurements in five patients, who were 
diagnosed to have chronic periodontitis and were not included in this study. PD and CAL 
measurements were repeated with two days intervals. The intraexaminer kappa scores were 
0.96 for PD and 0.85 for CAL. PD, CAL, bleeding on probing (BOP) (BOP deemed positive if 
bleeding occurred within 15 seconds after probing)20, and plaque index (PI)21 were recorded at 
six sites of all teeth present using a manual probe. In each patient, one site with the greatest PD 
in each quadrant was selected for GCF and subgingival plaque sampling.  
 
Saliva and serum sampling 
                                                          
‡ Hu-Friedy, Chicago, IL. 
§ Arkansas Stone SS4, Hu-Friedy, Chicago, IL. 
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In the morning, following an overnight fast, during which subjects were requested not to drink 
(except water) or to chew gum, whole saliva samples were obtained by expectorating into 
polypropylene tubes. The samples were immediately frozen and stored at -40ºC until the sample 
collection period was completed. 
Nine milliliters of venous blood were taken from the antecubital vein by a standard 
venipuncture method  and centrifuged for 10 minutes at 3000 rpm, separating serum from the 
cells. The serum samples were immediately frozen and stored at -40ºC. 
GCF and subgingival plaque sampling 
GCF samples were obtained from buccal aspects of one interproximal site in each quadrant.  
Supragingival plaque was removed carefully by sterile curettes; the surfaces were dried and 
isolated by cotton rolls. Filter paper strips‖ were placed in the orifice of the pocket for 30 
seconds. Care was taken to avoid mechanical trauma, and strips contaminated with blood were 
discarded. The absorbed GCF volume was estimated by a calibrated instrument¶. Then, the 
strips were placed into polypropylene tubes and immediately frozen and stored at -40ºC. GCF 
samples were converted to an actual volume (μL) by reference to a standard curve.  
Following GCF sample collection, subgingival plaque samples were collected from the 
same sites by sterile paper points#. Paper points inserted into the deepest part of the pocket and 
kept for 5 seconds, were then placed into sterile propylene tubes, immediately frozen and stored 
at -40ºC.  
Biochemical analyses 
Smoking status of each patient was determined by cotinine analysis in the salivary samples 
using an Enzyme Immunoassay (EIA)**. GCF samples from each patient were eluted in 1 mL 
of phosphate-buffered saline containing 0.05% polysorbate surfactant†† with a 60-minute 
incubation on a rotary mixer at +4ºC. Serum and saliva samples were used neat. Enzyme-linked 
immunosorbent assay (ELISA) kits were purchased for IL-17A, IL-17E, IL-17A/F, IL-6‡‡, IL-
                                                          
‖ Periopaper, ProFlow, Amytyville, NY. 
¶ Periotron 8000, Oraflow, Plainview, NY. 
# Diadent Group International, Seoul, Korea. 
**Alere toxicology, London, UK. 
††Tween 20, Sigma-Aldrich, Poole, UK. 
‡‡ R&D Systems, Abingdon, UK. 
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1β and TNF-α§§ analysis. The ELISA assays were carried out on 50 μL samples of GCF in 
duplicate and on 50 μL of serum/saliva in triplicate according to the manufacturers’ 
recommendations. The minimum detection limits in the assays were 1.9 pg/mL for IL-17A and 
IL-17E, 7.9 pg/mL for IL-17A/E, and 0.4 pg/mL for IL-1β and TNF-α, and 0.8 pg/ml for IL-6. 
The results were expressed as picograms per 30 seconds for the total amounts in the samples 
and as picograms per milliliter for concentrations.  
Preparation and assessment of genomic DNA  
A Gram-positive DNA isolation kit‖‖ was used to prepare genomic DNA from the pelleted 
microbes present in the paperpoint sample and from known quantities of laboratory strains of 
target microorganisms. The DNA in standards and plaque samples was measured by 
fluorimetric analysis¶¶. DNA content of the target species was used to fix the copy number of 
its bacterial genome to use as a standard for each realtime quantitative polymerase chain 
reaction (RTqPCR) assay. 
RT-qPCR 
Real-time reagents were purchased from##,*** and previously validated assays22 were used for 
detection and quantification of bacterial cell copy numbers in 1 µg plaque DNA for the 
following bacteria: P.gingivalis, A. actinomycetemcomitans, P. intermedia, P. micros, T. 
forsythia, F. nucleatum T. denticola S. mutans, F. nucleatum, S. oralis, A. naeslundi, V. dispar. 
The PCR reaction was performed on a thermocycler†††, under the following conditions: 10 
minutes at 95ºC and 40 cycles of 30 seconds at 95ºC and 1 minute at 60ºC. PCR assay efficiency 
was determined as follows: efficiency (E) = 10(-1/slope) -1 and deemed to be acceptable 
(between 91% and 104%). None of the primer amplified DNA purified from microbial 
standards other than the target species. 
 
 
Statistical analysis 
                                                          
§§ Thermo Fisher Renfrew, UK. 
‖‖ Masterpure, Illumina, San Diego, CA. 
¶¶ CyQUANT assay system, Invitrogen, Thermo Fisher Scientific, Waltham, MA. 
## Thermo Fisher Scientific, Paisley, UK. 
*** Eurogentech, Liege, Belgium. 
††† MRX3000 Agilent Thermocycler, Agilent, Edinburgh, UK. 
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Microsoft Excel and commercially available statistical softwares‡‡‡,§§§ were used to analyse the 
data. Sample size calculation included an estimated alpha error of 1% to allow for multiple 
testing of two treatment groups (smokers and non-smokers) and beta error of 20% with an effect 
size =1 for differences in the levels of biomarkers or copy numbers of several putative 
pathogens. For a two-sided test, a minimum of 27 subjects were required (13 in one group and 
14 in the other group) for a longitudinal study a minimum of 34 (17 per group) were selected 
to compensate for possible drop-outs during the course of the study and allow for initial cross-
sectional comparisons in an explorative study design. It was anticipated that larger effect sizes 
of 1.5 would be required in analyses where multiple testing was considered in cross-sectional 
analysis if there were any drop-outs from the study participants and  
alpha =0.01.  
Only the data of those patients who completed the entire study protocol were included in 
the longitudinal analyses. Cross-sectional analyses were performed on all available participants 
at each time point (see Fig. 1). Mean values of PD, CAL, and PI measurements were calculated 
for each patient and BOP was presented as percentages. CAL, PD, BOP, and PI data were 
compared between the study groups using Mann Whitney-U test. The Friedman test and Dunn's 
multiple comparison test was used for post hoc comparisons of the repeat sample tests. 
Although it was not relevant to the outcome, the baseline relationship between clinical, 
biochemical, and microbiological data was evaluated by Spearman correlation analysis.  
RESULTS 
 
Clinical measurements 
 
Four smoker and three non-smoker patients had to be excluded from the study due to their non-
compliance with appointments. The study was completed with 13 non-smoker patients (9 
females, 4 males) aged between 23-38 years (mean age 31.00±4.90) and 14 smoker patients (4 
females, 10 males) aged between 26-38 years (mean age 32.93±3.37). The study groups differed 
in gender distribution (p<0.05), but were similar in mean ages. The patients’ medical and dental 
histories, as well as socio-economical states were similar in the smoker and non-smoker groups. 
All patients had middle-income levels on the study registration forms and reported 12-14 years 
of education. The mean value of salivary cotinine concentration was 37.65 ng/ml in the smoker 
                                                          
‡‡‡ SPSS Inc. version 21 IBM, Chicago, IL. 
§§§ Graphpad Prism version 5, La Jolla. 
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group (min-max; 32.92-50.12 ng/ml) and 0.65 ng/ml in the non-smoker group (min-max; 0.48-
0.76 ng/ml) (p<0.001) (Table 1). Smoking habits of the patients did not change during the study. 
At baseline, the clinical periodontal measurements were similar in the smoker and non-
smoker patient groups (Table 2). At 1-month, PD, CAL, and BOP decreased significantly in 
the smoker group compared to the baseline (p<0.0001). The 3- and 6-month evaluations 
revealed significant reductions in all clinical periodontal parameters compared to the baseline 
values in both the smoker and non-smoker patient groups (p<0.0001). At 1-month, both groups 
revealed significant decreases in the number of sites with PD > 6 mm compared to the baseline 
(p<0.0001). Only the non-smoker group exhibited significant decreases in the counts and 
percentages of sites with PD > 6 mm at 3-month compared to the 1-month (p<0.0001) (Table 
2). 
 
Biochemical analysis 
Intergroup comparisons (i.e., between baseline and follow-up) revealed no statistically 
significant differences in serum IL-17A, IL-17E, IL-1β, TNF-α, IL-6 cytokine levels between 
the groups at majority of the time points (Fig. 1). At 1-month, IL-17E levels were higher in the 
non-smoker group (p<0.01). At 6-month, IL-17A levels were higher in the smoker group 
(p<0.01). Intragroup comparisons (i.e., between smokers and non-smokers) showed that TNF-
α and IL-6 decreased significantly at 1-month in both groups (p<0.0001). At 3-month IL-1β 
decreased only in the smoker group (p<0.0001), while both TNF-α and IL-6 exhibited 
significant decreases compared to the baseline values (p<0.0001). At 6-month, only IL-6 levels 
decreased significantly in both groups (p<0.0001). 
There were no intergroup differences in salivary cytokine levels at baseline (Fig. 2). At 
1-month, IL-17A and IL-1β levels were higher in the smoker group (p <0.01). At 3-month IL-
1β, and IL-6 levels were higher in the non-smoker group (p<0.01).  
The GCF sample volumes were similar in the smoker and non-smoker groups at baseline 
and decreased significantly in both groups at 1-, 3-, and 6-months (p<0.0001) (Table 1). At 
baseline, GCF cytokine levels were similar (Fig. 3). At 1-month; IL-17A levels were higher in 
the non-smoker group (p <0.01). There was no significant difference between the two groups 
in the 3-month GCF data (p>0.05).  
 
Microbiological analysis 
At baseline, copy numbers of P.gingivalis, P.intermedia, T.denticola and T. forsythia (Fig. 4) 
were higher in the smoker group (p<0.01). Gram-positive bacteria such as S. oralis were higher 
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in the non-smoker group (p<0.01) (Fig. 5). The frequency of carriage did not differ between 
smokers and non-smokers (data not shown). At 1-month, and at 3-month, the copy numbers of 
all bacteria were similar in both groups. At 6-month copy numbers of F. nucleatum, P. 
gingivalis, P. intermedia, S. oralis, T. denticola and T. forsythia were significantly higher in the 
smoker group (p<0.01). Similar results were obtained when the proportions of each organisms 
to the total bacterial DNA content were compared (data not shown). Total bacterial counts at 3- 
and 6-months were similar in both groups and decreased significantly from baseline to 1-, 3-, 
and 6-months (p <0.0001) (data not shown). 
 
Spearman correlations  
At baseline: although there were associations between clinical data (such as, PD, CAL, the 
number of sites with PD >5mm) and levels of certain cytokines TNF-α, IL-17A, IL-6 in serum 
and saliva (all Rho >0.32, p<0.05), levels of TNF-α, IL-17A, and IL-6 in GCF (all Rho>0.32, 
p<0.05) and several correlations were observed between IL-1β, TNF-α, IL-6 and IL-17A and 
microbiological parameters (all Rho>0.333, p<0.05). As anticipated these relationships were 
not observed following treatment.    
 
DISCUSSION 
 
Smoking is the most common modifiable risk factor for periodontitis worldwide and it is among 
the major determining factors for the grade of periodontitis in the 2017 classification.19 In the 
present study, the response to mechanical non-surgical periodontal treatment was evaluated 
comparatively in smoker and non-smoker patients with periodontitis stage III or IV, and grade 
C using clinical, biochemical and microbiological parameters. Baseline clinical periodontal 
status is of upmost importance when comparing the response to treatment among two or more 
study groups. The present study groups revealed similar baseline clinical findings in terms of 
oral hygiene, gingival inflammation and visual signs of tissue destruction. Moreover, the groups 
were comparable with regard to the socio-economic status and educational attainment. After 
non-surgical periodontal treatment, the clinical periodontal measurements decreased similarly 
in both smoker and non-smoker patients.  
Potential biomarkers for monitoring periodontal diseases may be sought in different 
biofluids; saliva, GCF, or serum. All these media have their own benefits; GCF provides site-
specific data, whereas saliva reflects the oral health as a whole and serum gives information 
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also about the systemic health or environmental factors such as smoking. In the present study, 
all three biofluid samples were investigated to have a comprehensive information. 
Adverse effects of smoking on clinical healing have been reported in previous  
studies23-28. Hughes et al.4 reported that smoker patients with GAgP did not respond well to 
non-surgical periodontal treatment. Smokers have been reported to have a higher risk for 
unresponsive pockets and further breakdown during supportive periodontal treatment.2 Non-
smoker patients with periodontitis exhibited better healing responses than smokers.16 However, 
another study reported contradicting data as both non-smokers and smokers exhibited similarly 
significant reductions in PD and bleeding scores between baseline and 6 months after non-
surgical periodontal treatment.29 Accordingly, the present study indicated similar outcomes for 
CAL and BOP in the smoker and non-smoker groups.  
Some studies suggest that the use of antibiotics in the treatment of aggressive 
periodontitis provides short-term benefits.30-32 Considering the potential side-effects33 together 
with limited benefits of short-term duration, no additional antibiotics were used in the present 
study.  
Suzuki et al.,34 found no correlation between GCF IL-1β levels and clinical parameters 
in AgP and the current study partly agreed with their results. Serum IL-17 affects the production 
of IL-1, IL-6 and TNF-α, and this cytokine was increased in AgP patients compared to healthy 
individuals and it was suggested to play a role in the pathogenesis of AgP.12 GCF IL-17A levels 
were found to be significantly elevated in patients with AgP.13 GAgP patients exhibited higher 
GCF IL-11:IL-17A ratio than healthy controls and this has been suggested to have a role in the 
pathogenesis of the disease.14 Teles et al.,35 also reported increased GCF levels of IL-1β:IL-10 
in patients with GAgP. On the other hand, patients with AgP have been shown to have higher 
serum and salivary IL-1β and pentraxin-3 concentrations than the healthy individuals.36 Similar 
findings have been reported for salivary TNF-α levels.28 In another study, serum concentrations 
of TNF-α, IL-4, IL-17A and IL-23 have been investigated in AgP patients at baseline and at 6-
months after SRP.37 The authors have documented higher IL-17A and TNF-α levels in AgP 
patients than those of healthy subjects. Moreover, TNF-α levels remained high in GAgP patients 
after treatment.  
De Lima Oliveira et al.38 stated that the IL-1β:IL-10 ratio may play an important role in 
the pathogenesis of AgP. Moreover, IL-17A, IL-23 and myeloperoxidase maintained high GCF 
levels in GAgP after SRP.39 Serum IL-17E levels have been suggested as a good indicator of 
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favourable treatment outcome in periodontitis patients after scaling and root-planing.40 Rosalem 
et al.8 found that GCF IL-1β levels decreased significantly 3 months after therapy in GAgP 
patients. Another study reported that GCF concentrations of IL-6 and TNF-α decreased from 
baseline to the 6-month in non-smokers as well as smokers.29 Although similar trends were 
observed, the current study agreed only in part with the earlier investigations presumably 
because of individual differences or by the complex nature of GAgP and possible presence of 
disease subgroups. This might be explained by the transient post-treatment falls and increases 
observed; paticularly for TNF-α. In the current study, IL-17E levels in biofluids other than 
serum decreased following non-surgical periodontal treatment. The reason for this difference 
remains obscure. However, other key cytokines such as TNF-α and IL-17A are increased in 
these biofluids and this may have a direct impact on local production of IL-17E. One might also 
speculate that the increase in pro-inflammatory cytokines TNF-α and IL-17A in GCF and saliva 
appears to coincide with a re-colonization of the tissue by pathogenic microorganisms. 
Correlations between several Gram-negative organisms and pro-inflammatory molecules were 
evident particularly at baseline, these associations were weaker during the follow-up after SRP, 
but this was probably due to the reduction in the number study participants as well as to the 
reduction in biomarker and bacterial counts.  
Significant positive correlations between PD, CAL, P. gingivalis and T. forsythia have 
been reported in GAgP patients.41 However, the current study indicated few correlations 
between the microorganisms and the clinical indices, and that these were only obseved at 
baseline. The major finding of the present study is that potentially pathogenic Gram-negative 
bacteria copy numbers were significantly higher in the smokers. In contrast to the smokers, 
non-smoker patients revealed higher copy numbers of Gram-positive bacteria. The present 
findings are in line with those of Darby et al.16 in terms of significantly higher detection rates 
of A. actinomycetemcomitans and P. intermedia in smoker patients than the non-smoker ones. 
While the results of the current study are not strictly analogous; the smoker group exhibited 
significantly higher copy numbers of P. intermedia, P. gingivalis, T. denticola and T. forsythia 
at baseline while the carriage frequencies were similar. The present finding of lower baseline 
proportions of P. gingivalis in non-smokers is parallel to the previous studies showing that 
smokers are more likely to harbor higher numbers of P. gingivalis, and to exhibit more 
persistent infection.42,43 Copy numbers of A. actinomycetemcomitans were higher in the smoker 
group at 1- and 6-months after treatment and the copy numbers of P. gingivalis, P.intermedia, 
T. denticola and T. forsythia were higher in the smoker group at 6-months. In the smoker 
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patients, carriage rates decreased following non-surgical periodontal treatment but incresed to 
the baseline levels by the 6-month reassessment and the copy numbers of Gram-negative 
bacteria increased to a greater extent in the smokers.  
The major limitation of the present study is the rather low number of patients mainly due 
to the stringent inclusion and exclusion criteria and the dropout of patients during the follow-
up period which resulted in some of the later cross-group comparisons having less than 80% 
statistical power. While the longitudinal component of the study retained sufficient statistical 
power (at an effect size =1) the follow-up period was shorter than desired because of the failure 
of sufficient patients to return at later time points. Another limitation may be the lack of blinding 
to the study group during the measurement of the clinical periodontal parameters as one 
researcher performed the SRP and clinical recordings in all patients. However, stainings on the 
teeth, increased gingival pigmentation, and the characteristic cigarette smell make blinding of 
the clinician extremely difficult if not impossible in studies that compare smokers and non-
smoker counterparts.  
 
CONCLUSION 
Within the limits of the present study, it may be concluded that smoker patients with 
periodontitis stage III or IV and grade C exhibit higher detection rates and faster recolonisation 
of Gram-negative bacteria in subgingival plaque samples. Further studies on a larger scale and 
longer follow-up periods are warranted to support the present findings. 
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Figure legends 
 
Figure 1. Cytokine levels in serum of smokers and non-smokers with aggressive periodontitis before 
and after non-surgical therapy. A. Serum IL-17A Level Changes B. Serum IL-17E  Level Changes C. 
Serum IL-17A/E Level Changes D. Serum IL-1β Level Changes E. Serum TNF-α Level Changes F. 
Serum IL-6 Level Changes  
*Significant difference between smokers and non-smokers (p<0.01) †Significant difference from 
baseline data in the group (p<0.0001). ‡Significant difference from 1-month data in the group 
(p<0.0001). §Significant difference from 3-month data in the group (p<0.0001). 
 
Figure 2. Cytokine levels in saliva of smokers and non-smokers with aggressive periodontitis before 
and after non-surgical therapy. A. Saliva IL-17A Level Changes B. Saliva IL-17E  Level Changes C. 
Saliva IL-17A/E Level Changes D. Saliva IL-1β Level Changes E. Saliva TNF-α Level Changes F. 
Saliva IL-6 Level Changes  
*Significant difference between smokers and non-smokers (p<0.01) †Significant difference from 
baseline data in the group (p<0.0001). ‡Significant difference from 1-month data in the group 
(p<0.0001). §Significant difference from 3-month data in the group (p<0.0001). 
Figure 3. Cytokine levels in GCF of smokers and non-smokers with aggressive periodontitis before and 
after non-surgical therapy. A. GCF IL-17A Level Changes B. GCF IL-17E  Level Changes C. GCF IL-
17A/E Level Changes D. GCF IL-1β Level Changes E. GCF TNF-α Level Changes F. GCF IL-6 Level 
Changes  
*Significant difference between smokers and non-smokers (p<0.01) †Significant difference from 
baseline data in the group (p<0.0001). ‡Significant difference from 1-month data in the group 
(p<0.0001). §Significant difference from 3-month data in the group (p<0.0001). 
Figure 4. Real-time PCR detection of Copy numbers of DNA from Gram negative bacteria. in the dental 
plaque of smokers and nonsmokers with Aggressive periodontitis before and after non-surgical therapy. 
A) A. actinomycetemcomitans, B) F. nucleatum,C) P. gingivalis, D) P. intermedia, E) P. oralis, F) T. 
denticola, G) T. forsythia, H) V. dispar. 
*Significant difference between smokers and non-smokers (p<0.01) †Significant difference from 
baseline data in the group (p<0.0001).   ‡Significant difference from 1-month data in the group 
(p<0.0001).  §Significant difference from 3-month data in the group (p<0.0001). 
 
Figure 5. Real-time PCR detection of Copy numbers of DNA from Gram positive  bacteria in the 
dental plaque of smokers and nonsmokers with Aggressive periodontitis before and after non-surgical 
therapy.  A) A. naeslundii, B) S. mitis, C) S. oralis. 
*Significant difference between smokers and non-smokers (p<0.01) †Significant difference from 
baseline data in the group (p<0.0001).  ‡Significant difference from 1-month data in the group 
(p<0.0001).    §Significant difference from 3-month data in the group (p<0.0001). 
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Table 1. Demographic findings in the study groups. 
Demographic Variable 
Non-smoker 
Group 
Smoker Group 
Patient count (n) 13 14 
Gender (female/ male) 9 / 4 4 / 10 
Age (year) (min - max) 23 - 38 26 - 38 
Age (year) 
(Mean ± SD) 
31.00 ± 4.90 32.93 ± 3.37 
Cigarette consumption/day 
(median (Q1-Q3)) 
0 (0-0) 15 (10-20) 
Pack-Year 
(Mean ± SD) 
0.00 ± 0.00 11.75 ± 4.76 
Cotinine 
(ng/ml) (median (Q1-Q3)) 
0.65 (0.48-0.76) 37.65 (32.92-50.12) 
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Table 2. Clinical periodontal findings in the study groups. All data are expressed as median 
(Q1-Q3) unless otherwise noted. 
Clinical variable  Time Non-smokers (n=13) Smokers (n=14) 
PD (full mouth) 
(mm) 
Baseline 4.19 (3.89-4.89) 4.43 (4.35-5.20) 
1. month 2.72 (2.52-3.50) 3.06 (2.87-3.48)* 
3. month 2.59 (2.40-3.26)* 2.89 (2.74-3.41)* 
6. month 2.58 (2.26-3.16)* 2.98 (2.82-3.27)* 
CAL (full mouth) 
(mm) 
Baseline 4.85 (4.28-5.02) 5.42 (4.40-6.25) 
1. month 4.18 (3.24-4.38) 4.57 (3.24-5.29)* 
3. month 3.82 (3.09-4.21)* 4.10 (3.11-4.87)* 
6. month 3.70 (2.91-4.14)*† 3.81 (3.29-5.16)* 
BOP (full mouth) 
(%) 
Baseline 79.76 (56.94-100.00) 66.87 (52.28-94.07) 
1. month 19,15 (15,48-24,01) 18,83 (9,17-26,60)* 
3. month 14.88 (12.90-17.76)* 15.91 (9.68-18.00)* 
6. month 15.48 (8.83-17.26)* 18.10 (7.86-21.83)* 
PI (full mouth) 
(0-5) 
Baseline 3.28 (3.12-3.59) 3.47 (3.28-3.57) 
1. month 2.43 (2.29-2.65)* 2.47 (2.23-2.63)* 
3. month 2.45 (2.21-2.60)* 2.31 (2.13-2.50)* 
6. month 2.48 (2.37-2.58)*‡ 2.19 (2.11-2.44)* 
PD (sample sites) 
(mm) 
Baseline 8.5 (7.25-9.50) 8.38 (7.44-9.69) 
1. month 4 (3.30-6.50)* 4.5 (4.25-5.63)* 
3. month 4 (3.75-5.50)* 4.63 (4.00-5.13)* 
6. month 3.75 (3.25-4.50)* 3.88 (3.50-4.25)* 
CAL (sample sites) 
(mm) 
Baseline 9 (7.25-10.00) 9 (7.00-10.00) 
1. month 5 (4.00-8.00)* 6 (4.00-8.00)* 
3. month 5 (3.25-7.00)* 5.50 (4.00-7.00)* 
6. month 4 (3.00-6.75)* 5 (4.00-6.25)* 
PD (sites with PD> 6 mm) 
(n) 
Baseline 21.00 (10.50-47.50) 29.00 (17.00-41.50) 
1. month 0.00 (0.00-24.00)* 2.50 (0.00-17.00)* 
3. month 0.00 (0.00-12.50)*† 2.00 (0.00-8.00)* 
6. month 0.00 (0.00-8.00)*† 0.50 (0.00-3.00)*†§ 
PD (sites with PD> 6 mm) 
(%) 
Baseline 13.46 (6.48-26.47) 17.90 (11.22-34.29) 
1. month 0.00 (0.00-14.29)* 1.93 (0.00-10.32)* 
3. month 0.00 (0.00-8.01)*† 1.26 (0.00-5.55)* 
6. month 0.00 (0.00-4.97)*†§ 0.33 (0.00-1.84)*†§ 
GCF volume (µl) 
 
Baseline 1 (0.67-1)‡ 0.71 (0.48-1) 
1. month 0.5 (0.24-0.67)* 0.42 (0.18-0.75)* 
3. month 0.46 (0.29-0.66)* 0.52 (0.18-0.8)* 
3. month 0.51 (0.28-0.66)* 0.45 (0.12-0.74)* 
* Significantly lower than the baseline value (p<0.0001). 
† Significantly lower than the 1-month value (p<0.0001). 
‡ Significantly difference between the study groups (p<0.05) 
§ Significantly lower than the 3-month value (p<0.0001). 
 
 
 
 
21 
Figure 1 
 
 
 
 
 
 
22 
Figure 2 
 
 
 
 
 
 
 
 
23 
Figure 3 
 
 
 
 
 
 
 
 
24 
Figure 4 
 
 
 
 
 
25 
Figure 5 
 
